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Background: Mammalian target of rapamycin (mTOR), a serine/threonine kinase, regulates many processes,
including cell growth and the immune response. mTOR is also dysregulated in several neurological diseases, such
as traumatic brain injury (TBI), stroke, and neurodegenerative disease. However, the role of mTOR in intracerebral
hemorrhage (ICH) remains unexplored. The aims of our study were to determine whether inhibiting mTOR signaling
could affect the outcome after ICH and to investigate the possible underlying mechanism.
Methods: A rat ICH model was induced by intracerebral injection of collagenase IV into the striatum, and mTOR
activation was inhibited by administration of rapamycin. mTOR signaling activation was determined by western
blotting. Neurobehavioral deficit after ICH was determined by a set of modified Neurological Severity Scores (mNSS).
The levels of CD4+CD25+Foxp3+ regulatory T cells (Tregs) and cytokines were examined using flow cytometry and
ELISA, respectively.
Results: Our results demonstrated thatmTOR signaling was activated 30 minutes and returned to its basal level 1 day
after ICH. Increased p-mTOR, which mean that mTOR signaling was activated, was predominantly located around the
hematoma. Rapamycin treatment significantly improved the neurobehavioral deficit after ICH, increased the number of
Tregs, increased levels of interleukin-10 and transforming growth factor-β and reduced interferon-γ both in peripheral
blood and brain.
Conclusions: Our study suggests that mTOR improves ICH outcome and modulates immune response after ICH.
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Stroke is the second leading cause of death worldwide
[1], and is one of the major causes of morbidity and
mortality. Intracerebral hemorrhage (ICH), a lethal type
of stroke, accounts for 20% of all strokes [2], and occurs
in about 50–60% of East Asians [3]. Currently, no spe-
cific therapies are available that improve the outcome
after ICH. Surgical treatment of ICH, such as surgical* Correspondence: zhugeqichuan@vip.163.com
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unless otherwise stated.removal of the hematoma, is primarily supportive, but
the clinical outcome is poor, increasing the potential
extensive burden for the family and society. Thus, the
problem of improving neurological disability after ICH is
still needs to be resolved.
In the early 1990s, the two yeast genes TOR1 and
TOR2 were discovered in the budding yeast Saccharomyces
cerevisiae by a group performing genetic screens for the
toxic effects of rapamycin [4]. Mammalian target of rapa-
mycin (mTOR) was then quickly identified, purified, and
cloned [5,6]. mTOR is an evolutionarily conserved serine/
threonine kinase that plays a key role in the regulation of
cell growth and metabolism [7]. The mTOR pathwayThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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processes including autophagy, ribosome biogenesis, tran-
scription, translation, and cytoskeletal organization [8,9].
In addition to cancer, dysregulation of mTOR activity
has been found in neural diseases, such as epilepsy
[10], Parkinson’s disease [11,12], Alzheimer’s disease
[13], and traumatic brain injury (TBI) [14]. Chen et al.
found in a model of TBI that mTOR was significantly
phosphorylated from 30 minutes to 24 hours after TBI.
Considering the role of mTOR in regulating mRNA
translation for cell growth, dendritic arborization, and
hippocampal synaptic plasticity, its activation may con-
tribute to the deficits in learning and memory after TBI
[14]. However, the questions of whether mTOR is also ac-
tivated after ICH, and whether activation of mTOR related
to neurobehavioral deficits still need to be determined.
An increasing number of studies have shown that
inflammatory responses are deeply involved in the pro-
gression of ICH-induced brain injury [15,16], which may
be mediated by: 1) cellular components including local
microglia, lymphocytes, and leukocytes, and 2) molecu-
lar components including pro-inflammatory and anti-
inflammatory cytokines. These two major components
interact with each other and contribute to the outcome
of stroke [17,18]. Thymus-derived CD4+CD25+Foxp3+
regulatory T cells (Tregs) are known to be neuroprotec-
tive in stroke [19] by modulating the function of effector
T cells and secreting anti-inflammatory molecules such
as interleukin (IL)-10 and transforming growth factor
(TGF)-β [20,21]. Recent studies have shown that mTOR
is proving to be a vital link between immune function
and metabolism, and inhibition of mTOR by rapamycin
promotes the production of CD4+CD25+Foxp3+ Tregs
[22,23]. Thus, the question arises as to whether inhib-
ition of mTOR might also improve neurological disabil-
ity by modulating the immune response after ICH.
In order to address the issues described above, we first
investigated alterations of the mTOR signaling pathway
around the hematoma after ICH, and then examined the
effect of rapamycin treatment on neurological deficits
after ICH. Finally, we explored the effect of rapamycin ad-
ministration on immune response in a rat model of ICH.
Materials and methods
All experimental procedures were approved by the Animal
Care Committee of the Wenzhou Medical University.
Animals
In total, 102 male Sprague–Dawley rats, weighing 280 to
320 g, were randomly divided into eight groups. Group
1 (n = 9) was the normal control group and did not re-
ceive any treatment; group 2 was the ICH group (n = 26),
which received collagenase injection at 30 minutes, 1
hour, 4 hour, 1 day, and 3 days after induction of stroke;group 3, the AU group (n = 8), received injection of
autologous blood; group 4, the PBS group (n = 6), received
PBS (containing 2.5% DMSO, 5% polyethylene glycol 400
and 5% Tween 80) 1 hour after ICH; groups 5 to 8 were
treated with rapamycin (n = 53) at concentration of 50
(n = 11), 150 (n = 23), 250 (n = 11), and 500 ug/kg (n = 11),
respectively, via intraperitoneal injection.
ICH model
The experimental ICH model was induced by intras-
triatal collagenase injection, as previously described by
Rosenberg et al. [24]. Briefly, rats were anesthetized
using 4% chloral hydrate and then placed in a stereo-
taxic frame (KOPF, California, USA) After the bregma
was exposed, a borehole (1 mm) was drilled 3 mm lateral
to the bregma and then a 30-gauge needle was inserted
through the bore hole into the striatum (5 mm ventral
from the skull surface).
For the collagenase-injection model, 1 μl collagenase
type IV (0.25 IU/μl) was injected into the striatum over
a period of 5 minutes to induce ICH. The needle was
allowed to remain in situ for another 5 minutes before it
was removed.
For the autologous blood-injection model, 50 μl au-
tologous blood, which was withdrawn from the caudal
artery, was injected into the striatum in a double-
injection manner, as described previously by Deinsberger
et al. [25]. During injection, the temperature was moni-
tored and maintained at 37 ± 0.5°C. Animals recovered
at room temperature with free access to food and water
under a 12-hour light/dark cycle.
Rapamycin
Rapamycin (Merck Millipore, Darmstadt, Germany) was
dissolved in DMSO (5 mg/ml) and stored at −20°C. Be-
fore injection, rapamycin was diluted with PBS contain-
ing 5% polyethylene glycol 400 and 5% Tween 80. The
ICH rats received a single intraperitoneal injection of
rapamycin 1 hour after collagenase administration, and
the doses of rapamycin used were 50, 150, 250, and 500
μg/kg for groups 5 to 8, respectively.
Western blot analysis
In order to assess the profile of mTOR activation after
ICH, rats were euthanized at 30 minutes, 1 hour, 4
hours, 1 day, 3 days, or 7 days after ICH. The brains
were removed, and the left (ipsilateral) and right (contra-
lateral) hemispheres were separated. The tissues were
then homogenized in RIPA buffer (Thermo, Rockford,
USA) containing 10 μl of protease inhibitors and phos-
phatase inhibitors (Thermo) per 1 ml RIPA. The protein
concentration was determined by bicinchoninic acid assay
(Thermo). Equivalent quantities of protein (50 μg per
lane) were separated in 6 to 15% SDS-polyacrylamide gels,
Figure 1 Mammalian target of rapamycin (mTOR) was activated after intracerebral hemorrhage (ICH). (A) Protein from the ipsilateral
hemisphere was analyzed by western blotting using anti-p-mTOR (Ser 2448)., which was was greatly increased at 30 minutes after ICH and lasted
up to 14 days after ICH. The level of p-mTOR was normalized to the level of tubulin. *P<0.05.
Figure 2 Increased mammalian target of rapamycin (mTOR) activation in the ipsilateral striatum after intracerebral hemorrhage (ICH).
(A) Protein from the striatum was analyzed by western blotting using anti-p-mTOR (Ser 2448). The level of p-mTOR was normalized to the level of
tubulin. The p-mTOR significantly increased at 30 minutes after ICH, and returned to basal level at 1 day after ICH. (B) The change in total mTOR
was not significant after being normalized to tubulin. *P<0.05; **P<0.001.
Lu et al. Journal of Neuroinflammation 2014, 11:44 Page 3 of 13
http://www.jneuroinflammation.com/content/11/1/44
Lu et al. Journal of Neuroinflammation 2014, 11:44 Page 4 of 13
http://www.jneuroinflammation.com/content/11/1/44and transferred to PVDF membranes. After blocking, the
membranes were incubated overnight at 4°C with the fol-
lowing primary antibodies: rabbit anti-mTOR monoclonal
antibody, rabbit anti-p-mTOR (Ser 2448) polyclonal anti-
body, rabbit anti-phospho -p70S6 (Thr 389) monoclonal
antibody, rabbit anti-p70S6 monoclonal antibody, rabbit
anti-tubulin polyclonal antibody (1:1000) (all from Cell
Signaling Technology). After washing three times in TBS
buffer with 0.1% Tween (TBS-T), membranes were further
incubated with HRP-conjugated anti-rabbit IgG secondary
antibody for 1 h at room temperature, and the bands were
visualized by enhanced chemiluminescence (Thermo, USA)
and X-ray film(Thermo, USA) exposure. Quantity One
software (BioRad) was used to detect the band intensities.
To ensure reproducibility, all experiments were repeated
at least three times.Behavioral testing
For behavioral testing, rats were assessed before ICH
and at 1, 3, 7, and 14 days after ICH by an investigator
who was blinded to the experimental groups using a set
of modified Neurological Severity Scores (mNSS) [26,27].
The mNSS is a complex behavioral test including motor,
sensory, reflex, and balance tests. In this test, the scores
ranged from 0 to 18, where 0 was considered normal and
18 was maximum deficit.Figure 3 Mammalian target of rapamycin (mTOR) activation in the ip
both (A) p-mTOR and (B) total mTOR did not show significant changes aftFlow cytometry
At 3 days after ICH, control rats (n = 6), ICH rats (n = 8),
and rats treated with 150 μg/kg rapamycin (n = 10) were
euthanized and perfused with saline. The blood and brain
of each rat were collected, and the monocytes were sep-
arated as described previously [28]. Cells were stained
with antibodies (BD Biosciences): FITC–anti-rat-CD4,
APC-anti-rat-CD25, and PE-anti-rat-FoxP3. Stained cells
were analyzed by blinded evaluators using a flow cyto-
meter (FACSCalibur; BD Biosciences, USA) and Flowjo
7.6 software.ELISA
To test the inflammatory response after rapamycin treat-
ment, colorimetric ELISA kits were used to detect the
following cytokines in serum and brain protein extract:
rat IL-10, rat interferon (IFN)-γ, and rat TGF-β (all R&D
Systems, USA). For each ELISA analysis, 40 μl of sample
was used without dilution in accordance with the manu-
facturer's instructions.Statistical analysis
Data areshown as means ± standard deviation (SD). Stat-
istical differences between normal control group and
other groups were compared using student T-tests. Stat-
istical significance was defined as *P<0.05 and **P<0.001.silateral cortex after intracerebral hemorrhage (ICH). The levels of
er ICH (after normalization to tubulin).
Figure 4 Increased p70S6 activation in the ipsilateral striatum after intracerebral hemorrhage (ICH). (A) Protein from the striatum was
analyzed by western blotting using anti-p-p70S6 (Thr 389). The level of p-p70S6 was normalized to the level of tubulin. p-mTOR was significantly
increased at 1 hour and returned to basal level at 1 day after ICH. (B) The change in total p70S6 was not significant after being normalized to
tubulin. *P<0.05.
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Alteration of mTOR signaling pathway after ICH
To study alterations in the mTOR signaling pathway
after ICH, protein lysis samples from the ipsilateral
hemisphere were separated by electrophoresis and ana-
lyzed by western blotting. We found increased phosphor-
ylation of mTOR in the ipsilateral hemisphere of ICH rats
from 30 minutes to 14 days after ICH (Figure 1), suggest-
ing that activation of mTOR signaling was both rapid and
long-lasting after ICH.
To further study the profile of mTOR activation in dif-
ferent regions of the ipsilateral hemisphere, we analyzed
the protein from the striatum surrounding the hematoma
and cortex (both regions extended 2 mm around the nee-
dle tip) by western blotting. We observed that mTOR
phosphorylation in the ipsilateral striatum was signifi-
cantly increased at 30 minutes, peaked at 1 hour, and
returned to basal level about 1 day after ICH (Figure 2).
The level of total mTOR was not significantly changed
after ICH., and the mTOR activation level in the cortex
was not significantly activated after ICH (Figure 3).
To detect whether mTOR signaling was also activated
following ICH, western blotting was performed using
anti-p70 ribosomal S6 kinase (p70S6), one of the main
downstream targets of the mTOR signaling [29-31]. Com-
pared with the control group, phosphorylation of p70S6was also activated at 1 hour after ICH (Figure 4), but the
level of total p70S6 was not significantly changed after ICH.
Effect of rapamycin on the neurobehavior of ICH rats
To determine the role of mTOR signaling after ICH,
rapamycin, an mTOR inhibitor, was injected intraperito-
neally at 1 hour after ICH. Neurobehavioral function
was evaluated in different groups using the mNSS. Rats
were trained 3 days before ICH to assess the normal
level (score = 0). At 1 day after ICH, the mean mNSS
values were 9.56 ± 0.68 in the ICH group, 9.50 ± 0.50 in
the PBS group, 9.00 ± 0.67 in the 50 μg/kg rapamycin-
treated group, 8.00 ± 0.67 in the 150 μg/kg rapamycin-
treated group, and 7.11 ± 0.74 in the 250 μg/kg
rapamycin-treated group (Figure 5). Statistical analysis
showed significant differences between the ICH group
and the rapamycin-treated groups (except the 50 μg/kg
group and 500 μg/kg group). Results for neurobehav-
ioral outcomes at 3, 7 and 14 days after ICH were simi-
lar to those given above for 1 day after ICH. There were
no significant differences between the ICH group and
the PBS group. These results suggest that rapamycin sig-
nificantly improved the functional recovery of the ICH
rats in a dose-dependent manner. However, we found
that rats treated with the highest concentration of rapa-
mycin (500 μg/kg) were too sick to be evaluated and six
Figure 6 Rapamycin inhibited p-mammalian target of rapamycin (mT
(ICH) group (4 h after ICH), significantly lower levels of p-mTOR were obser
significant change in the 50 μg/kg treated group. (B) The total mTOR level
p-mTOR and total mTOR were normalized to tubulin. *P<0.05; **P<0.001.
Figure 5 Rapamycin improves recovery of neurobehavioral
function after intracerebral hemorrhage (ICH). The scores in both
the ICH and rapamycin groups were similar before ICH. At 1 hour after
ICH, rapamycin-treated groups were injected with rapamycin using
different concentrations: 50, 150, 250, and 500 μg/kg. The behaviors
were evaluated and compared at 1, 3, 7, and 14 days after ICH. We
observed a significant functional recovery in rapamycin-treated groups
compared with the ICH group. The mean modified Neurological
Severity Score (mNSS) values ± SEM are depicted, *P<0.05; ** P<0.001
compared with ICH rats.
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were no significant differences between the 150 μg/kg
and the 250 μg/kg groups at each time point, we
propose that the best dose of rapamycin for ICH treat-
ment is 150 μg/kg.
Rapamycin improves the neurobehavioral deficits in rats
after ICH by mTOR signaling
In order to assess whether rapamycin improved func-
tional recovery by inhibiting mTOR signaling, rats were
euthanized 4 hours after receiving rapamycin (at various
concentrations). As shown in Figure 6, rapamycin treat-
ment (150, 250 and 500 μg/kg, but not 50 μg/kg) sig-
nificantly reduced the p-mTOR level in the striatum.
Although higher concentrations of rapamycin had a
stronger inhibition on p-mTOR, there was no signifi-
cant difference between the groups treated with 150
and 250 μg/kg, further suggesting that 150 μg/kg is the
best dose of rapamycin for ICH treatment.
Rapamycin increases Tregs in the peripheral blood and
ipsilateral hemisphere
In order to evaluate the effects of rapamycin on the
immune response of ICH rats, we separated monocytes
from peripheral blood and brain as described previously
[28], and analyzed the level of CD4+CD25+Foxp3+
Tregs was analyzed by flow cytometry. The control andOR) in the striatum. (A) Compared with the intracerebral hemorrhage
ved in the 150, 250, and 500 μg/kg treated groups while there was no
in rapamycin-treated groups was similar to that of the ICH group. Both
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Tregs in the peripheral blood (0.931 ± 0.145% and
1.035 ± 0.207%, respectively). However, the group
treated with 150 μg/kg rapamycin had a significantly
higher level of CD4+Foxp3+ Tregs (1.797 ± 0.434%)
than the other two groups (Figure 7). Similar to the find-
ings for peripheral blood, CD4+Foxp3+ Tregs in the ipsi-
lateral hemisphere (Figure 8) were increased in the group
treated with 150 μg/kg rapamycin (3.103 ± 0.170%), and
no significant difference was observed between the con-
trol (1.599 ± 0.031%) and ICH (1.407 ± 0.179%) groups.
The results indicated that rapamycin could expand
CD4+CD25+FoxP3+ Tregs in the peripheral blood and
ipsilateral hemisphere.
Effect of rapamycin on cytokines in peripheral blood and
ipsilateral hemisphere
To further study the effect of rapamycin on cytokines
after ICH, we examined the level of IFN-γ and IL-10Figure 7 Rapamycin increased the level of regulatory T cells (Tregs) i
lymphocytes derived from (A) control group, (B) intracerebral hemorrhage (IC
graph for the three groups. There were significant differences between the co
rapamycin-treated groups. *P<0.05.in the peripheral blood and around the intracerebral
hematoma by ELISA. As shown in Figures 9 and 10, the
level of IFN-γ was substantially downregulated both in
serum and around the hematoma after treatment with
rapamycin (Figures 9A and 10A), whereas the levels
of IL-10 and TGF-β were upregulated (Figure 9B,D;
Figure 10B,D). The ratio of IL-10 to IFN-γ was signifi-
cantly higher in rapamycin-treated groups (Figures 9C
and 10C). The increased IL-10 and TGF-β, and decreased
IFN-γ levels imply that rapamycin modulates inflamma-
tory response in peripheral blood and brain after ICH.
Effect of rapamycin on immune response in the
autologous blood-injection model of ICH
Considering that collagenase can induce some cerebral
inflammation, we explored the effect of rapamycin
(150 μg/kg) on immune response in the autologous
blood-injection model of ICH. We found that rapamy-
cin also decreased the level of IFN-γ and increasedn the blood. Dot plots labeled with CD4 and Foxp3 show the blood
H) group, and (C) 150 μg/kg rapamycin-treated group. (D) A statistical
ntrol group and rapamycin-treated groups, and between the ICH and
Figure 8 Rapamycin increased the level of regulatory T cells (Tregs) in the ipsilateral hemisphere. Dot plots labeled with CD4 and Foxp3
show the brain lymphocytes from (A) control group, (B) intracerebral hemorrhage (ICH) group, and (C) 150 μg/kg rapamycin-treated group.
(D) A statistical graph for the three groups. There were significantly higher levels of Tregs in the rapamycin-treated group than the control
and ICH groups. *P<0.001.
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hematoma in the autologous blood-injection model
(Figure 11). Although the level of IFN-γ was higher in the
collagenase-injection model than in the autologous blood-
injection model after ICH, there was no significant differ-
ence between the two models (Figure 11A,B), suggesting
that collagenase could induce inflammation, but did not
significantly increase the level of IFN-γ. These results
further suggest the anti-inflammatory effect of rapamy-
cin after ICH.
Discussion
In the present study, we found evidence that the mTOR
signaling was activated 30 minutes after ICH, and
returned to its basal level 1 day after ICH. The in-
creased p-mTOR was predominantly located around
the hematoma. Rapamycin treatment significantly im-
proved the neurobehavioral deficit after ICH, andincreased the number of Tregs, along with the levels of
IL-10 and TGF-β, and reduced the level IFN-γ both in
peripheral blood and brain. Our study suggests that
mTOR improves ICH outcome and modulates immune
response after ICH.
mTOR plays a crucial role in regulating many activ-
ities, including protein synthesis, cell growth, and cell
death. Accumulating evidence indicates that mTOR is
dysregulated in various brain diseases, and inhibition of
mTOR by rapamycin provides neuroprotective effects.
In a mouse model of tuberous sclerosis complex, Zeng
et al. found that mTOR signaling is widespread and is
stimulated by acute seizure activity, and that rapamycin
treatment could reduce mossy fiber sprouting and epi-
lepsy [10]. In a TBI model, Chen et al. found that mTOR
was significantly activated from 30 minutes to 24 hours
and may contribute to the deficits in learning and
memory after TBI [14], while Erlich et al. demonstrated
Figure 9 Levels of cytokines in the serum after rapamycin treatment. (A) The levels of interferon (IFN)-γ in each rapamycin-treated group
were lower than the intracerebral hemorrhage (ICH) group. (B) Rapamycin-treated groups presented higher interleukin (IL)-10 expression than
the ICH group. (C) The ratio of interleukin (IL)-10 to IFN-γ increased after treatment with rapamycin (150, 250, and 500 μg/kg, but not 50 μg/kg).
(D) Rapamycin increased the level of transforming growth factor (TGF)-β. There were no significant differences between the 150, 250, and
500 μg/kg rapamycin-treated groups. *P<0.05.
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ing TBI reduced microglial activation and increased the
number of surviving neurons at the site of injury to im-
prove functional recovery [32]. In a model of neonatal
hypoxia-ischemia, Carloni et al. showed that rapamycin
increased autophagy, reduced necrotic cell death, and
decreased brain injury [33]. In a dog model of sub-
arachnoid hemorrhage (SAH), Zhang et al. found that
mTOR signaling was activated in vascular smooth
muscle cells, which contributed to cerebral vasospasm
following SAH injury, and that rapamycin could inhibit
mTOR signaling and attenuate angiographic vasospasm
[34]. Consistently, our study indicated that mTOR was
upregulated after ICH, and the outcome was signifi-
cantly improved through inhibition of mTOR by rapa-
mycin. Our data suggest that mTOR may be a potential
therapeutic target for ICH.mTOR plays a key role in the inflammatory and im-
mune responses [35], which can sense and integrate cues
from the microenvironment to control activation and de-
velopment of immune cells, including T cells and micro-
glia. Microglia, innate immune cells residing in the CNS,
contribute to initiation and maintenance of cerebral in-
flammation, release pro-inflammatory mediators that are
potentially cytotoxic, and exert detrimental effects when
activated permanently [36]. Cinzia et al. showed that
mTOR selectively controls microglial activation in re-
sponse to pro-inflammatory cytokines, and appears to play
a crucial role in microglial viability [37]. In our study,
mTOR was increased around the hematoma, which may
relate to the activation of microglia and release of pro-
inflammatory cytokines. Injection of rapamycin at dif-
ferent concentrations (including 150, 250, and 500 μg/kg)
significantly decreased the level of IFN-γ and increased
Figure 10 Levels of cytokines around the hematoma after rapamycin treatment. (A) Compared with the intracerebral hemorrhage (ICH)
group, the levels of interferon (IFN)-γ were reduced in the rapamycin-treated groups except for the 50 μg/kg group. (B) Rapamycin-treated
groups had higher levels of interleukin (IL)-10 than the ICH group, except for the 50 μg/kg group. (C) The ratio of IL-10 to IFN-γ was increased
after treatment with rapamycin (150, 250, and 500 μg/kg, but not 50 μg/kg). (D) Rapamycin increased the level of transforming growth factor
(TGF)-β. *P<0.05.
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in serum.
IFN-γ is a key regulator of immune and inflammatory
responses. In various neural diseases, IFN-γ is produced
by infiltrating T cells, and is associated with onset and
process of pathology [38]. IFN-γ was shown to induce
the expression of TNF, IL-1β, nitric oxide synthase, and
oxygen synthase [39,40], all of which could aggravate the
neural disabilities after ICH. By contrast, IL-10, an
anti-inflammatory cytokine, was shown to limit in-
flammation in the brain by reducing the synthesis of
pro-inflammatory cytokines, and suppressing expres-
sion and activation of the cytokine receptor [41]. In
addition, Sharma et al. found that IL-10 increased
neuronal survival after exposure to oxygen-glucose
deprivation by inducing phosphorylation of pro-survival
pathways such as AKT and STAT-3 signaling in vitro [42].
Thus, by upregulating IL-10 and downregulating IFN-γ 4
hours after ICH, rapamycin plays an anti-inflammatoryrole in the peripheral blood and brain at an early stage,
which could decrease brain damage and contribute to
neural recovery.
At the same time, TGF-β is a pleiotropic cytokine
with a central role in inflammation. In a murine stroke
model, injection of TGF-β1 into the lesion border
zone greatly reduced infarct bleeding by recruiting
bone marrow-derived monocytes/macrophages, which
are important for maintaining integrity of the neuro-
vascular unit following brain ischemia [43]. In humans
with stroke, levels of TGF-β1 were found to be in-
creased in the ischemic penumbra, which is essential
for angiogenesis after stroke [44]. Abundant studies
have shown that TGF-β can induce angiogenesis and
neurogenesis following stroke [45-47]. Considering the
role of TGF-β in angiogenesis and neurogenesis, rapa-
mycin may promote functional recovery after ICH by
increasing the levels of TGF-β in the blood and brain,
as shown by our study.
Figure 11 Effect of rapamycin on the levels of interferon (IFN)-γ and interleukin (IL)-10 at an autologous blood-injection model of
intracerebral hemorrhage (ICH). (A, B) Similar to the collagenase-injection model, the levels of IFN-γ was downregulated after treatment with
rapamycin both in serum and around the hematoma in an autologous blood-injection model. (C, D) Rapamycin upregulated IL-10 both in serum
and around the hematoma. AU, Autologous blood-injection model of ICH, CO, Collagenase-injection model of ICH, RA, Rapamycin. *P<0.05.
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liferate and differentiate to T helper type 1 (Th1) cells,
Th2 cells and Th17 cells, which favor the generation of
Tregs [48,49]. In a model of acute experimental stroke,
Liesz et al. found that depletion of Tregs profoundly de-
layed brain damage and deteriorated functional outcome
after injection of anti-CD25 antibody. They concluded
that Tregs were major cerebroprotective modulators of
postischemic inflammatory brain damage through IL-10
signaling [19]. In the present study, we found that Tregs
were significantly increased in peripheral blood and ipsi-
lateral hemisphere at 3 days after rapamycin injection.
Taken together, these results show that the increased
Treg numbers and altered cytokines may be associated
with improved outcome after repamycin treatment.
Conclusion
Our study provides the first evidence that the mTOR
signaling pathway is abnormally activated in brain after
ICH, especially around the hematoma. Secondly, rapa-
mycin treatment given 1 hour after ICH can promoteneurologic functional recovery. Lastly, the underlying
mechanisms may be the effect of rapamycin in regulating
inflammatory and immune responses, including upregula-
tion of IL-10, TGF-β, and Tregs, and downregulation of
IFN-γ. Therefore, mTOR may be a novel therapeutic
target for ICH.Abbreviations
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